Eli Lilly (LLY) R&D In Process (2016 - 2025)
Historic R&D In Process for Eli Lilly (LLY) over the last 16 years, with Q3 2025 value amounting to $655.7 million.
- Eli Lilly's R&D In Process fell 7683.04% to $655.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 billion, marking a year-over-year decrease of 3080.65%. This contributed to the annual value of $3.3 billion for FY2024, which is 1367.37% down from last year.
- Per Eli Lilly's latest filing, its R&D In Process stood at $655.7 million for Q3 2025, which was down 7683.04% from $153.8 million recorded in Q2 2025.
- Eli Lilly's 5-year R&D In Process high stood at $3.0 billion for Q3 2023, and its period low was $25.0 million during Q2 2021.
- For the 5-year period, Eli Lilly's R&D In Process averaged around $597.2 million, with its median value being $189.2 million (2024).
- Its R&D In Process has fluctuated over the past 5 years, first plummeted by 8966.09% in 2021, then surged by 467564.1% in 2023.
- Eli Lilly's R&D In Process (Quarter) stood at $471.8 million in 2021, then plummeted by 49.11% to $240.1 million in 2022, then surged by 158.23% to $620.0 million in 2023, then tumbled by 69.48% to $189.2 million in 2024, then surged by 246.56% to $655.7 million in 2025.
- Its R&D In Process was $655.7 million in Q3 2025, compared to $153.8 million in Q2 2025 and $1.6 billion in Q1 2025.